RxDoctor Payments Data

John Larson, APRN

Psychiatric/Mental Health · Lafayette, LANPI 1144783408

Payments from drug & device makers

$2,682in general payments, 2019–2025

Across 180 payments — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Neurocrine Biosciences, Inc.$448
  • Teva Pharmaceuticals USA, Inc.$380
  • Otsuka America Pharmaceutical, Inc.$161
  • Alkermes, Inc.$161
  • Johnson & Johnson$159
  • plus $252 from 7 others

What the payments were for

  • Food & beverage$2,61097%
  • Education$713%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,682 in reported general payments places this provider in the 70th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$4,950
Medicare patients
31
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl48$69,821
Invega SustennaPaliperidone Palmitate17$47,387
CaplytaLumateperone Tosylate18$32,077
RexultiBrexpiprazole14$19,785
BelsomraSuvorexant13$6,027
Ziprasidone Hcl23$4,036
Doxepin Hcl87$3,897
Quetiapine Fumarate139$3,221
Ramelteon11$2,930
Lurasidone Hcl80$2,616
Aripiprazole135$2,600
Buspirone Hcl225$2,498
Divalproex Sodium ErDivalproex Sodium57$2,378
Oxcarbazepine50$1,759
Bupropion XlBupropion Hcl95$1,624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,122$69,82148 claims
Johnson & JohnsonInvega Sustenna$159$47,38717 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$20$32,07718 claims
Otsuka America Pharmaceutical, Inc.Rexulti$161$19,78514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →